Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia

Oncotarget

Volumn 6, Issue 36, 2015, Pages 38804-38815

  Wobus, Manja ^a   Bornhäuser, Martin ^a,c   Jacobi, Angela ^b   Kräter, Martin ^a   Otto, Oliver ^b   Ortlepp, Claudia ^a   Guck, Jochen ^b   Ehninger, Gerhard ^a   Thiede, Christian ^a   Oelschlägel, Uta ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c German Consortium for Translational Cancer Research (DKTK)   (Germany)

Author keywords

AML; Bone marrow microenvironment; CD97; FLT3 ITD

Indexed keywords

5 CHLORO 3 [(3,5 DIMETHYL 2 PYRROLYL)METHYLENE] 2 INDOLINONE; CD135 ANTIGEN; CD34 ANTIGEN; CD97 ANTIGEN; HEMOGLOBIN; LYSOPHOSPHATIDIC ACID; MIDOSTAURIN; NUCLEOPHOSMIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; CD97 PROTEIN, HUMAN; FLT3 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BONE MARROW BLAST CELL; CELL ADHESION; CELL COUNT; CELL DEFORMABILITY; CELL MIGRATION; CELL SIZE; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CONTROLLED STUDY; FETAL CALF SERUM; FLOW CYTOMETRY; FLT3 GENE; GENE DUPLICATION; GENE MUTATION; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNAL TANDEM DUPLICATION; MONOCYTE; NPM1 GENE; PROTEIN EXPRESSION; ACUTE MYELOID LEUKEMIA; BIOSYNTHESIS; ENZYMOLOGY; GENE SILENCING; GENETICS; HEK293 CELL LINE; HL-60 CELL LINE; METABOLISM; PATHOLOGY; TANDEM REPEAT; TUMOR CELL LINE;

ANTIGENS, CD; CELL LINE, TUMOR; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; TANDEM REPEAT SEQUENCES;

EID: 84948745097     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5661     Document Type: Article

References (33)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341:1051-1062.
2. Malfuson JV, Boutin L, Clay D, Thepenier C, Desterke C, Torossian F, Guerton B, Anginot A, de RT, Lataillade JJ, Le Bousse-Kerdiles MC. SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis. Leukemia. 2014; 28:853-864.
3. Ekpenyong AE, Whyte G, Chalut K, Pagliara S, Lautenschlager F, Fiddler C, Paschke S, Keyser UF, Chilvers ER, Guck J. Viscoelastic properties of differentiating blood cells are fate- and function-dependent. PLoS One. 2012; 7:e45237.
4. Lautenschlager F, Paschke S, Schinkinger S, Bruel A, Beil M, Guck J. The regulatory role of cell mechanics for migration of differentiating myeloid cells. Proc Natl Acad Sci U S A. 2009; 106:15696-15701.
5. Lam WA, Rosenbluth MJ, Fletcher DA. Chemotherapy exposure increases leukemia cell stiffness. Blood. 2007; 109:3505-3508.
6. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, Illmer T. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99:4326-4335.
7. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001; 98:1752-1759.
8. Eichler W, Hamann J, Aust G. Expression characteristics of the human CD97 antigen. Tissue Antigens. 1997; 50:429-438.
9. Safaee M, Clark AJ, Ivan ME, Oh MC, Bloch O, Sun MZ, Oh T, Parsa AT. CD97 is a multifunctional leukocyte receptor with distinct roles in human cancers (Review). Int J Oncol. 2013; 43:1343-1350.
10. Hamann J, Vogel B, van Schijndel GM, van Lier RA. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med. 1996; 184:1185-1189.
11. Stacey M, Chang GW, Davies JQ, Kwakkenbos MJ, Sanderson RD, Hamann J, Gordon S, Lin HH. The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood. 2003; 102:2916-2924.
12. Wandel E, Saalbach A, Sittig D, Gebhardt C, Aust G. Thy-1 (CD90) is an interacting partner for CD97 on activated endothelial cells. J Immunol. 2012; 188:1442-1450.
13. Wang T, Ward Y, Tian L, Lake R, Guedez L, Stetler-Stevenson WG, Kelly K. CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood. 2005; 105:2836-2844.
14. Aust G, Eichler W, Laue S, Lehmann I, Heldin NE, Lotz O, Scherbaum WA, Dralle H, Hoang-Vu C. CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res. 1997; 57:1798-1806.
15. Steinert M, Wobus M, Boltze C, Schutz A, Wahlbuhl M, Hamann J, Aust G. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol. 2002; 161:1657-1667.
16. Ward Y, Lake R, Yin JJ, Heger CD, Raffeld M, Goldsmith PK, Merino M, Kelly K. LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res. 2011; 71:7301-7311.
17. Ahmad N, Haider S, Jagannathan S, Anaissie E, Driscoll JJ. MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia. 2014; 28:732-738.
18. van Pel M, Hagoort H, Hamann J, Fibbe WE. CD97 is differentially expressed on murine hematopoietic stem-and progenitor-cells. Haematologica. 2008; 93:1137-1144.
19. van Pel M, Hagoort H, Kwakkenbos MJ, Hamann J, Fibbe WE. Differential role of CD97 in interleukin-8-induced and granulocyte-colony stimulating factor-induced hematopoietic stem and progenitor cell mobilization. Haematologica. 2008; 93:601-604.
20. Veninga H, Hoek RM, de Vos AF, de Bruin AM, An FQ, van der Poll T, van Lier RA, Medof ME, Hamann J. A novel role for CD55 in granulocyte homeostasis and anti-bacterial host defense. PLoS One. 2011; 6:e24431.
21. Bonardi F, Fusetti F, Deelen P, van GD, Vellenga E, Schuringa JJ. A proteomics and transcriptomics approach to identify leukemic stem cell (LSC) markers. Mol Cell Proteomics. 2013; 12:626-637.
22. Mirkowska P, Hofmann A, Sedek L, Slamova L, Mejstrikova E, Szczepanski T, Schmitz M, Cario G, Stanulla M, Schrappe M, van der Velden VH, Bornhauser BC, Wollscheid B, Bourquin JP. Leukemia surfaceome analysis reveals new disease-associated features. Blood. 2013; 121:149-159.
23. Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui CH, Downing JR, Campana D. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011; 117:6267-6276.
24. Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol. 2011; 4:13 10.1186/1756-8722-4-13.
25. Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res. 2003; 9:2140-2150.
26. Ortlepp C, Steudel C, Heiderich C, Koch S, Jacobi A, Ryser M, Brenner S, Bornhauser M, Brors B, Hofmann WK, Ehninger G, Thiede C. Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation. Exp Hematol. 2013; 41:444-461.
27. Galle J, Sittig D, Hanisch I, Wobus M, Wandel E, Loeffler M, Aust G. Individual Cell-Based Models of Tumor-Environment Interactions: Multiple Effects of CD97 on Tumor Invasion. Am J Pathol. 2006; 169:1802-1811.
28. Fukuda S, Broxmeyer HE, Pelus LM. Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/CXCR4 axis. Blood. 2005; 105:3117-3126.
29. Otto O, Rosendahl P, Mietke A, Golfier S, Herold C, Klaue D, Girardo S, Pagliara S, Ekpenyong A, Jacobi A, Wobus M, Topfner N, Keyser UF, Mansfeld J, Fischer-Friedrich E, Guck J. Real-time deformability cytometry: on-the-fly cell mechanical phenotyping. Nat Methods. 2015; 12:199-202.
30. Faure S, Salazar-Fontana LI, Semichon M, Tybulewicz VL, Bismuth G, Trautmann A, Germain RN, Delon J. ERM proteins regulate cytoskeleton relaxation promoting T cell-APC conjugation. Nat Immunol. 2004; 5:272-279.
31. Tabe Y, Konopleva M. Advances in understanding the leukaemia microenvironment. Br J Haematol. 2014; 164:767-778.
32. Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat. 2009; 12:103-113.
33. Kwakkenbos MJ, Pouwels W, Matmati M, Stacey M, Lin HH, Gordon S, van Lier RA, Hamann J. Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J Leukoc Biol. 2005; 77:112-119.